Icon to validate PROs as measurement of clinical endpoints for the FDA

ICON has been selected by the FDA to validate patient-reported outcome as endpoints for antibacterial drug clinical trials. (Vic/flickr)

The U.S. FDA has selected Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials.

With the help of the Biomarkers Consortium of the Foundation for the National Institutes of Health, Icon’s Clinical Outcomes Assessment group will develop an electronic platform to validate PROs.

Clinical trials use PRO instruments—often patient-filled questionnaires with documents supporting their use—to measure treatment outcomes, usually for the purpose of labeling.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

The PRO instruments the CRO will help validate this time are used in trials of drugs treating acute bacterial skin and skin structure infections (ABSSSI), and bacterial pneumonia acquired either in community or healthcare settings.

Hospital-acquired bacterial pneumonia (HABP) is the second most common hospital-acquired infection and is the primary cause of death in ICUs, according to the CRO, while both community-acquired bacterial pneumonia and ABSSSI occur at higher rates.

The PROs will be implemented on CRF Health’s TrialMax eCOA platform, allowing patients to access the application from a handheld device during trials, said the company in a press release.

This is not the first time the two partners were tapped by the FDA to work on PROs. In November 2014, the FDA selected the pair to jointly design a replicable PRO measure for studies targeting HABP.

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.